HRMS or Hrams?

Ramanathan, Ragu; Korfmacher, Walter A.

doi:10.4155/bio-2016-0145

Cited by 6 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The resolving power should be such that it can provide mass accuracy sufficient to assign a unique elemental composition from the spectral peak as is needed in the elucidation of the chemical structure [90,93]. Ramanathan and Korfmacher [94] describe HRMS as " … with nominal mass accuracy, one can distinguish an analyte of 520 Da (nominal mass) from an analyte of 521 Da (nominal mass). With high mass accuracy, one can distinguish an analyte of 520.2000 Da (exact mass) from an analyte of 520.2371 Da (exact mass)".…”

Section: High Resolution Mass Spectrometry (Hrms)mentioning

confidence: 99%

What the lab can and cannot do: clinical interpretation of drug testing results

Kapur¹,

Aleksa²

2020

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

Urine drug testing is one of the objective tools available to assess adherence. To monitor adherence, quantitative urinary results can assist in differentiating "new" drug use from "previous" (historical) drug use. "Spikes" in urinary concentration can assist in identifying patterns of drug use. Coupled chromatographic-mass spectrometric methods are capable of identifying very small amounts of analyte and can make clinical interpretation rather challenging, specifically for drugs that have a longer half-life. Polypharmacy is common in treatment and rehabilitation programs because of co-morbidities. Medications prescribed for comorbidities can cause drug-drug interaction and phenoconversion of genotypic extensive metabolizers into phenotypic poor metabolizers of the treatment drug. This can have significant impact on both pharmacokinetic (PK) and pharmacodynamic properties of the treatment drug. Therapeutic drug monitoring (TDM) coupled with PKs can assist in interpreting the effects of phenoconversion. TDM-PKs reflects the cumulative effects of pathophysiological changes in the patient as well as drug-drug interactions and should be considered for treatment medications/drugs used to manage pain and treat substance abuse. Since only a few enzyme immunoassays for TDM are available, this is a unique opportunity for clinical laboratory scientists to develop TDM-PK protocols that can have a significant impact on patient care and personalized medicine. Interpretation of drug screening results should be done with caution while considering pharmacological properties and the presence or absence of the parent drug and its metabolites. The objective of this manuscript is to review and address the variables that influence interpretation of different drugs analyzed from a rehabilitation and treatment programs perspective.

show abstract

Section: High Resolution Mass Spectrometry (Hrms)mentioning

confidence: 99%

What the lab can and cannot do: clinical interpretation of drug testing results

Kapur¹,

Aleksa²

2020

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

show abstract

“…The 2013 publications expanded the focus to include regulated bioanalysis, peptide quantitation and protein therapeutics as well as editorials and opinions The 2016 special issue of Bioanalysis, which focuses on HRMS, is a collection of articles that updates and expands the scope of how HRMS is being used by scientists engaged in various aspects of new drug discovery and drug development. This issue includes an opinion on HRMS as well as a commentary on HRMS [17,18]. The opinion discusses the rationales between the abbreviations/terminology HRMS and high-resolution accurate MS.…”

mentioning

confidence: 99%

HRMS in DMPK

Korfmacher

Ramanathan

2016

Bioanalysis

Self Cite

View full text Add to dashboard Cite

“…Even the terminology is easily misunderstood. Often, it seems that the terms high-resolution a ccurate MS (HRAM or HRAMS) or HRMS are used interchangeably [2][3][4]. There is also a lack of understanding about this technology by external regulatory experts, corporate compliance and scientists, which causes unnecessary anxiety and controversy regarding the regulatory aspects of HRMS.…”

mentioning

confidence: 99%

Liquid Chromatography-High-Resolution Mass Spectrometry for Regulated Bioanalysis: Bile Acid and Oligonucleotide Quantitation as A Reference

Mei

2016

Bioanalysis

View full text Add to dashboard Cite

HRMS or Hrams?

Cited by 6 publications

References 5 publications

What the lab can and cannot do: clinical interpretation of drug testing results

What the lab can and cannot do: clinical interpretation of drug testing results

HRMS in DMPK

Liquid Chromatography-High-Resolution Mass Spectrometry for Regulated Bioanalysis: Bile Acid and Oligonucleotide Quantitation as A Reference

Contact Info

Product

Resources

About